{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:57:24Z","timestamp":1793339844473,"version":"4.5.0"},"reference-count":205,"publisher":"Portland Press Ltd.","issue":"18","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in the liver in combination with metabolic dysfunction in the form of overweight or obesity and insulin resistance. It is also associated with an increased cardiovascular disease risk, including hypertension and atherosclerosis. Hepatic lipid metabolism is regulated by a combination of the uptake and export of fatty acids, de novo lipogenesis, and fat utilization by \u03b2-oxidation. When the balance between these pathways is altered, hepatic lipid accumulation commences, and long-term activation of inflammatory and fibrotic pathways can progress to worsen the liver disease. This review discusses the details of the molecular mechanisms regulating hepatic lipids and the emerging therapies targeting these pathways as potential future treatments for MAFLD.<\/jats:p>","DOI":"10.1042\/cs20220572","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:21:38Z","timestamp":1663921298000},"page":"1347-1366","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":373,"title":["Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways"],"prefix":"10.1042","volume":"136","author":[{"given":"Olufunto\u00a0O.","family":"Badmus","sequence":"first","affiliation":[{"name":"1Department of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah\u00a0A.","family":"Hillhouse","sequence":"additional","affiliation":[{"name":"1Department of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher\u00a0D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Department of Surgery, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Terry\u00a0D.","family":"Hinds","sequence":"additional","affiliation":[{"name":"3Department of Pharmacology and Nutritional Sciences, Barnstable Brown Diabetes Center, Markey Cancer Center, University of Kentucky, Lexington, KY 40508, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-4008","authenticated-orcid":false,"given":"David\u00a0E.","family":"Stec","sequence":"additional","affiliation":[{"name":"1Department of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"2022092308210108600_B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2022092308210108600_B2","doi-asserted-by":"publisher","first-page":"1999e1","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"2022092308210108600_B3","doi-asserted-by":"publisher","first-page":"e036663","DOI":"10.1136\/bmjopen-2019-036663","article-title":"Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study","volume":"10","author":"Ge","year":"2020","journal-title":"BMJ Open"},{"key":"2022092308210108600_B4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"2022092308210108600_B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ncp.10449","article-title":"Evolution of NAFLD and its management","volume":"35","author":"Mundi","year":"2020","journal-title":"Nutr. Clin. Pract."},{"key":"2022092308210108600_B6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"2022092308210108600_B7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"2022092308210108600_B8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000282080","article-title":"Epidemiology of non-alcoholic fatty liver disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig. Dis."},{"key":"2022092308210108600_B9","doi-asserted-by":"publisher","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci. Rep."},{"key":"2022092308210108600_B10","doi-asserted-by":"publisher","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"2022092308210108600_B11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1152\/physrev.00024.2006","article-title":"Disordered lipid metabolism and the pathogenesis of insulin resistance","volume":"87","author":"Savage","year":"2007","journal-title":"Physiol. Rev."},{"key":"2022092308210108600_B12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"key":"2022092308210108600_B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab."},{"key":"2022092308210108600_B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-2004-823104","article-title":"The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis","volume":"24","author":"Wanless","year":"2004","journal-title":"Semin. Liver Dis."},{"key":"2022092308210108600_B15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2022092308210108600_B16","first-page":"622","article-title":"Proteins involved in lipid metabolism as possible biomarkers or predisposing factors for non-alcoholic fatty liver disease","volume":"83","author":"Oliveros-Montiel","year":"2020","journal-title":"Acta Gastroenterol. Belg."},{"key":"2022092308210108600_B17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.2214\/AJR.11.6729","article-title":"MRI steatosis grading: development and initial validation of a color mapping system","volume":"198","author":"Qayyum","year":"2012","journal-title":"AJR. Am. J. Roentgenol."},{"key":"2022092308210108600_B18","first-page":"167","article-title":"Pathogenesis and prevention of hepatic steatosis","volume":"11","author":"Nassir","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2022092308210108600_B19","doi-asserted-by":"publisher","first-page":"E249","DOI":"10.1152\/ajpendo.00478.2015","article-title":"The glucocorticoid receptor: cause of or cure for obesity?","volume":"310","author":"John","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2022092308210108600_B20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tem.2015.02.001","article-title":"Biliverdin reductase isozymes in metabolism","volume":"26","author":"O'Brien","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"2022092308210108600_B21","doi-asserted-by":"publisher","first-page":"E191","DOI":"10.1152\/ajpendo.00405.2020","article-title":"Bilirubin as a metabolic hormone: the physiological relevance of low levels","volume":"320","author":"Creeden","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2022092308210108600_B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10030387","article-title":"Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice","volume":"10","author":"Stec","year":"2020","journal-title":"Biomolecules"},{"key":"2022092308210108600_B23","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010004","article-title":"Adipose-specific PPARalpha knockout mice have increased lipogenesis by PASK-SREBP1 signaling and a polarity shift to inflammatory macrophages in white adipose tissue","volume":"11","author":"Hinds","year":"2021","journal-title":"Cells"},{"key":"2022092308210108600_B24","first-page":"30","article-title":"What is the real function of the liver \u2018function\u2019 tests?","volume":"81","author":"Hall","year":"2012","journal-title":"Ulster Med. J."},{"key":"2022092308210108600_B25","first-page":"147","article-title":"Alcoholic liver disease: pathogenesis and current management","volume":"38","author":"Osna","year":"2017","journal-title":"Alcohol Res."},{"key":"2022092308210108600_B26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11906-019-0994-z","article-title":"Bilirubin safeguards cardiorenal and metabolic diseases: a protective role in health","volume":"21","author":"Hinds","year":"2019","journal-title":"Curr. Hypertens. Rep."},{"key":"2022092308210108600_B27","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/HYPERTENSIONAHA.118.11130","article-title":"Bilirubin, a cardiometabolic signaling molecule","volume":"72","author":"Hinds","year":"2018","journal-title":"Hypertension"},{"key":"2022092308210108600_B28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tem.2018.01.002","article-title":"Bilirubin in the liver-gut signaling axis","volume":"29","author":"Hamoud","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"2022092308210108600_B29","doi-asserted-by":"publisher","first-page":"594574","DOI":"10.3389\/fphar.2020.594574","article-title":"Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fat utilization, and increase plasma beta-hydroxybutyrate","volume":"11","author":"Hinds","year":"2020","journal-title":"Front. Pharmacol."},{"key":"2022092308210108600_B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013700","article-title":"Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor alpha","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"2022092308210108600_B31","first-page":"2016","article-title":"Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha","author":"Hinds","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2022092308210108600_B32","doi-asserted-by":"publisher","first-page":"e0153427","DOI":"10.1371\/journal.pone.0153427","article-title":"Bilirubin Binding to PPARalpha Inhibits Lipid Accumulation","volume":"11","author":"Stec","year":"2016","journal-title":"PloS ONE"},{"key":"2022092308210108600_B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249493","article-title":"Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease","volume":"21","author":"Stec","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2022092308210108600_B34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2036.2008.03896.x","article-title":"Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels","volume":"29","author":"Wong","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2022092308210108600_B35","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/hep4.1971","article-title":"A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis","volume":"6","author":"Eguchi","year":"2022","journal-title":"Hepatol. Commun."},{"key":"2022092308210108600_B36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MEG.0000000000000502","article-title":"Serum beta-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis","volume":"28","author":"Cengiz","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"2022092308210108600_B37","doi-asserted-by":"publisher","first-page":"e2630","DOI":"10.1097\/MD.0000000000002630","article-title":"Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines","volume":"95","author":"Jamali","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"2022092308210108600_B38","doi-asserted-by":"publisher","first-page":"G668","DOI":"10.1152\/ajpgi.00026.2018","article-title":"Biliverdin reductase and bilirubin in hepatic disease","volume":"314","author":"Weaver","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2022092308210108600_B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32467","article-title":"Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents","author":"Creeden","year":"2022","journal-title":"Hepatology"},{"key":"2022092308210108600_B40","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9010199","article-title":"Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"9","author":"Burz","year":"2021","journal-title":"Microorganisms"},{"key":"2022092308210108600_B41","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.4049\/jimmunol.166.4.2651","article-title":"Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta","volume":"166","author":"Seki","year":"2001","journal-title":"J. Immunol."},{"key":"2022092308210108600_B42","doi-asserted-by":"publisher","first-page":"R733","DOI":"10.1152\/ajpregu.00153.2019","article-title":"Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet-induced obesity","volume":"317","author":"Stec","year":"2019","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2022092308210108600_B43","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10060395","article-title":"Could SCGF-Beta Levels Be Associated with Inflammation Markers and Insulin Resistance in Male Patients Suffering from Obesity-Related NAFLD?","volume":"10","author":"Tarantino","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2022092308210108600_B44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12876-021-01773-x","article-title":"Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?","volume":"21","author":"Yen","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"2022092308210108600_B45","first-page":"65","article-title":"Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients","volume":"24","author":"Peterson","year":"1992","journal-title":"Ital. J. Gastroenterol."},{"key":"2022092308210108600_B46","first-page":"155","article-title":"Increased insulin binding to erythrocytes in chronic liver disease","volume":"35","author":"Okada","year":"1981","journal-title":"Acta Med. Okayama"},{"key":"2022092308210108600_B47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/BF01737009","article-title":"Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis","volume":"65","author":"Petrides","year":"1987","journal-title":"Klin. Wochenschr."},{"key":"2022092308210108600_B48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1210\/jcem-55-3-524","article-title":"Down-regulation of insulin receptors in postnecrotic cirrhosis of liver","volume":"55","author":"Teng","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2022092308210108600_B49","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/s-2007-999204","article-title":"Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes","volume":"12","author":"Greco","year":"1980","journal-title":"Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme"},{"key":"2022092308210108600_B50","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/0026-0495(82)90011-7","article-title":"Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes","volume":"31","author":"Harewood","year":"1982","journal-title":"Metabolism"},{"key":"2022092308210108600_B51","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci.:CMLS"},{"key":"2022092308210108600_B52","doi-asserted-by":"publisher","first-page":"51664","DOI":"10.1074\/jbc.M309377200","article-title":"Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene","volume":"278","author":"Newberry","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2022092308210108600_B53","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/hep.21369","article-title":"Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice","volume":"44","author":"Newberry","year":"2006","journal-title":"Hepatology"},{"key":"2022092308210108600_B54","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/2211-5463.12240","article-title":"Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease","volume":"7","author":"Mukai","year":"2017","journal-title":"FEBS Open Bio."},{"key":"2022092308210108600_B55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7150\/ijms.40417","article-title":"Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"17","author":"Lu","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"2022092308210108600_B56","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1194\/jlr.R056705","article-title":"Recent insights into the biological functions of liver fatty acid binding protein 1","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"2022092308210108600_B57","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","article-title":"Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis","volume":"130","author":"Doege","year":"2006","journal-title":"Gastroenterology"},{"key":"2022092308210108600_B58","doi-asserted-by":"publisher","first-page":"22186","DOI":"10.1074\/jbc.M803510200","article-title":"Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia","volume":"283","author":"Doege","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2022092308210108600_B59","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1055\/s-0030-1267186","article-title":"A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis","volume":"42","author":"Auinger","year":"2010","journal-title":"Hormone and Metabolic Res. = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme"},{"key":"2022092308210108600_B60","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.2337\/db07-0907","article-title":"Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity","volume":"56","author":"Koonen","year":"2007","journal-title":"Diabetes"},{"key":"2022092308210108600_B61","doi-asserted-by":"publisher","first-page":"e0145626","DOI":"10.1371\/journal.pone.0145626","article-title":"Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model","volume":"11","author":"Buttet","year":"2016","journal-title":"PloS ONE"},{"key":"2022092308210108600_B62","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina","year":"2011","journal-title":"Gut"},{"key":"2022092308210108600_B63","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"2022092308210108600_B64","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/978-3-030-78315-0_17","article-title":"Bilirubin: A Ligand of the PPAR\u03b1 Nuclear Receptor","volume-title":"Nuclear Receptors: The Art and Science of Modulator Design and Discovery","author":"Hong","year":"2021"},{"key":"2022092308210108600_B65","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"2022092308210108600_B66","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/hep.21752","article-title":"Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes","volume":"46","author":"Joshi-Barve","year":"2007","journal-title":"Hepatology"},{"key":"2022092308210108600_B67","doi-asserted-by":"publisher","first-page":"e31812","DOI":"10.1371\/journal.pone.0031812","article-title":"Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass","volume":"7","author":"Knebel","year":"2012","journal-title":"PloS ONE"},{"key":"2022092308210108600_B68","doi-asserted-by":"publisher","first-page":"587189","DOI":"10.3389\/fendo.2020.587189","article-title":"ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue","volume":"11","author":"Iizuka","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2022092308210108600_B69","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1073\/pnas.0401516101","article-title":"Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis","volume":"101","author":"Iizuka","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2022092308210108600_B70","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/db06-0200","article-title":"Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob\/ob mice","volume":"55","author":"Dentin","year":"2006","journal-title":"Diabetes"},{"key":"2022092308210108600_B71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93626","article-title":"Peroxisomal beta-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease","volume":"3","author":"Moreno-Fernandez","year":"2018","journal-title":"JCI Insight"},{"key":"2022092308210108600_B72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mehy.2016.08.013","article-title":"Does bilirubin prevent hepatic steatosis through activation of the PPARalpha nuclear receptor?","volume":"95","author":"Hinds","year":"2016","journal-title":"Med. Hypotheses"},{"key":"2022092308210108600_B73","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.731703","article-title":"Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) alpha","author":"Hinds","year":"2016","journal-title":"J. Biol. Chem."},{"key":"2022092308210108600_B74","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"2022092308210108600_B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062061","article-title":"PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2022092308210108600_B76","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1172\/JCI32752","article-title":"Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents","volume":"118","author":"Ota","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2022092308210108600_B77","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/liv.12220","article-title":"MTTP polymorphisms and susceptibility to non-alcoholic fatty liver disease in a Han Chinese population","volume":"34","author":"Peng","year":"2014","journal-title":"Liver Int."},{"key":"2022092308210108600_B78","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jhep.2009.12.033","article-title":"Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model","volume":"52","author":"Shindo","year":"2010","journal-title":"J. Hepatol."},{"key":"2022092308210108600_B79","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatology"},{"key":"2022092308210108600_B80","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.4254\/wjh.v7.i16.2041","article-title":"Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Whitsett","year":"2015","journal-title":"World J. Hepatol."},{"key":"2022092308210108600_B81","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"2022092308210108600_B82","doi-asserted-by":"publisher","first-page":"47898","DOI":"10.1074\/jbc.M408149200","article-title":"AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells","volume":"279","author":"Zang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2022092308210108600_B83","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1139\/y06-005","article-title":"AMP-activated protein kinase\u2013the fat controller of the energy railroad","volume":"84","author":"Steinberg","year":"2006","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2022092308210108600_B84","doi-asserted-by":"publisher","first-page":"e91111","DOI":"10.1371\/journal.pone.0091111","article-title":"Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity","volume":"9","author":"Woo","year":"2014","journal-title":"PloS ONE"},{"key":"2022092308210108600_B85","doi-asserted-by":"publisher","first-page":"689111","DOI":"10.3389\/fphar.2021.689111","article-title":"Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"2022092308210108600_B86","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/hep.23206","article-title":"Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin","volume":"50","author":"Romero-Gomez","year":"2009","journal-title":"Hepatology"},{"key":"2022092308210108600_B87","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1665-2681(19)31902-7","article-title":"Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions","volume":"6","author":"Duseja","year":"2007","journal-title":"Ann. Hepatol."},{"key":"2022092308210108600_B88","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1345\/aph.1P099","article-title":"Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease","volume":"44","author":"Cone","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"2022092308210108600_B89","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.2337\/dc11-2306","article-title":"Metformin-induced hepatotoxicity","volume":"35","author":"Miralles-Linares","year":"2012","journal-title":"Diabetes Care."},{"key":"2022092308210108600_B90","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019","volume":"42","author":"American Diabetes","year":"2019","journal-title":"Diabetes Care."},{"key":"2022092308210108600_B91","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2022092308210108600_B92","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"key":"2022092308210108600_B93","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"key":"2022092308210108600_B94","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"2022092308210108600_B95","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci. Rep."},{"key":"2022092308210108600_B96","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab."},{"key":"2022092308210108600_B97","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"2022092308210108600_B98","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"2022092308210108600_B99","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"2022092308210108600_B100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr"},{"key":"2022092308210108600_B101","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2022092308210108600_B102","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"2022092308210108600_B103","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1038\/ajg.2010.363","article-title":"Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series","volume":"105","author":"Kenny","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"2022092308210108600_B104","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4254\/wjh.v12.i8.493","article-title":"Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update","volume":"12","author":"Sofogianni","year":"2020","journal-title":"World J. Hepatol."},{"key":"2022092308210108600_B105","doi-asserted-by":"publisher","first-page":"1864307","DOI":"10.1155\/2018\/1864307","article-title":"Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL\/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway","volume":"2018","author":"Shao","year":"2018","journal-title":"Gastroenterol Res. Pract."},{"key":"2022092308210108600_B106","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int."},{"key":"2022092308210108600_B107","doi-asserted-by":"publisher","first-page":"e3292","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"2022092308210108600_B108","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease","volume":"24","author":"Sayari","year":"2018","journal-title":"Clin. Mol. Hepatol."},{"key":"2022092308210108600_B109","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db10-1338","article-title":"Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice","volume":"60","author":"Shirakawa","year":"2011","journal-title":"Diabetes"},{"key":"2022092308210108600_B110","first-page":"3121","article-title":"Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1\/AMPKalpha pathway","volume":"16","author":"Shen","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"2022092308210108600_B111","first-page":"240","article-title":"Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis","volume":"75","author":"Yilmaz","year":"2012","journal-title":"Acta Gastroenterol. Belg."},{"key":"2022092308210108600_B112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"2022092308210108600_B113","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.2147\/DMSO.S262284","article-title":"Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Chen","year":"2020","journal-title":"Diab. Metab. Syndrome Obesity:Targets Therapy"},{"key":"2022092308210108600_B114","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2022092308210108600_B115","doi-asserted-by":"publisher","first-page":"558e2","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2022092308210108600_B116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.20452\/pamw.1023","article-title":"Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease","volume":"121","author":"Saryusz-Wolska","year":"2011","journal-title":"Pol. Arch. Med. Wewn."},{"key":"2022092308210108600_B117","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0929-6646(09)60202-3","article-title":"Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease","volume":"105","author":"Wang","year":"2006","journal-title":"J. Formos. Med. Assoc."},{"key":"2022092308210108600_B118","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"2022092308210108600_B119","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"2022092308210108600_B120","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1124\/jpet.121.000786","article-title":"Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model","volume":"379","author":"Tamura","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2022092308210108600_B121","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"2022092308210108600_B122","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbrc.2015.08.055","article-title":"Fatty acid transport protein-2 inhibitor Grassofermata\/CB5 protects cells against lipid accumulation and toxicity","volume":"465","author":"Saini","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2022092308210108600_B123","doi-asserted-by":"publisher","first-page":"106004","DOI":"10.1016\/j.phrs.2021.106004","article-title":"Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-beta1 pathway: therapeutic role of roflumilast","volume":"175","author":"Tao","year":"2022","journal-title":"Pharmacol. Res."},{"key":"2022092308210108600_B124","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.tem.2021.08.003","article-title":"FKBP51 and the molecular chaperoning of metabolism","volume":"32","author":"Smedlund","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"2022092308210108600_B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/6218637","article-title":"Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPAR\u03b3and Suppresses Adipogenesis","volume":"2016","author":"Hinds","year":"2016","journal-title":"PPAR Res."},{"key":"2022092308210108600_B126","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbrc.2014.03.103","article-title":"Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis","volume":"447","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2022092308210108600_B127","doi-asserted-by":"publisher","first-page":"e00076","DOI":"10.1002\/prp2.76","article-title":"Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation","volume":"2","author":"Hinds","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"2022092308210108600_B128","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1742-7843.2009.00427.x","article-title":"Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK\/HlJ mice","volume":"105","author":"Chang","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"2022092308210108600_B129","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00153.2019","article-title":"The loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet-induced obesity","author":"Stec","year":"2019","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2022092308210108600_B130","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071638","article-title":"Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"key":"2022092308210108600_B131","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"2022092308210108600_B132","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"2022092308210108600_B133","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jnutbio.2016.09.015","article-title":"PPARalpha protects against trans-fatty-acid-containing diet-induced steatohepatitis","volume":"39","author":"Hu","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"2022092308210108600_B134","doi-asserted-by":"publisher","first-page":"CD009580","DOI":"10.1002\/14651858.CD009580.pub2","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"2022092308210108600_B135","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care."},{"key":"2022092308210108600_B136","doi-asserted-by":"publisher","first-page":"l5125","DOI":"10.1136\/bmj.l5125","article-title":"Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study","volume":"366","author":"Kim","year":"2019","journal-title":"BMJ"},{"key":"2022092308210108600_B137","first-page":"211","article-title":"The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage","volume":"4","author":"Fatani","year":"2011","journal-title":"Int. J. Gen. Med."},{"key":"2022092308210108600_B138","doi-asserted-by":"publisher","first-page":"770652","DOI":"10.3389\/fphar.2021.770652","article-title":"Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7\/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"2022092308210108600_B139","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1478-3231.2006.01265.x","article-title":"Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver","volume":"26","author":"Harano","year":"2006","journal-title":"Liver Int."},{"key":"2022092308210108600_B140","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4254\/wjh.v5.i9.470","article-title":"Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease","volume":"5","author":"Kostapanos","year":"2013","journal-title":"World J. Hepatol."},{"key":"2022092308210108600_B141","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/fcp.12597","article-title":"Protective effect of fenofibrate against high-fat-high-fructose diet induced non-obese NAFLD in rats","volume":"35","author":"Abdelmoneim","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"2022092308210108600_B142","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jhep.2005.10.033","article-title":"Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates","volume":"44","author":"Shiri-Sverdlov","year":"2006","journal-title":"J. Hepatol."},{"key":"2022092308210108600_B143","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2011.03.009","article-title":"PPARalpha activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH","volume":"218","author":"Baron","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022092308210108600_B144","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1194\/jlr.M070631","article-title":"Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase","volume":"58","author":"van der Veen","year":"2017","journal-title":"J. Lipid Res."},{"key":"2022092308210108600_B145","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/hmg\/ddz290","article-title":"Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia","volume":"29","author":"Yavarow","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"2022092308210108600_B146","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jdi.12621","article-title":"Selective peroxisome proliferator-activated receptor-alpha modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-alpha pathway and improves lipid metabolism in mice","volume":"8","author":"Takei","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"2022092308210108600_B147","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial","volume":"25","author":"Arai","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"2022092308210108600_B148","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/584296","article-title":"PPARalpha in Obesity: Sex Difference and Estrogen Involvement","volume":"2010","author":"Yoon","year":"2010","journal-title":"PPAR Res."},{"key":"2022092308210108600_B149","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/oby.2007.171","article-title":"Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen","volume":"15","author":"Jeong","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"2022092308210108600_B150","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2009.02.004","article-title":"The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions","volume":"60","author":"Yoon","year":"2009","journal-title":"Pharmacol. Res."},{"key":"2022092308210108600_B151","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/19768354.2013.831772","article-title":"17\u03b2-estradiol inhibits PPAR\u03b1 of skeletal muscle","volume":"17","author":"Lee","year":"2013","journal-title":"Animal Cells and Systems"},{"key":"2022092308210108600_B152","doi-asserted-by":"publisher","first-page":"e00136","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPARalpha\/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"2022092308210108600_B153","doi-asserted-by":"publisher","first-page":"4810672","DOI":"10.1155\/2017\/4810672","article-title":"Deciphering the Roles of Thiazolidinediones and PPARgamma in Bladder Cancer","volume":"2017","author":"Chiu","year":"2017","journal-title":"PPAR Res."},{"key":"2022092308210108600_B154","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR alpha\/gamma Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci. Rep."},{"key":"2022092308210108600_B155","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacol. Toxicol."},{"key":"2022092308210108600_B156","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"2022092308210108600_B157","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"2022092308210108600_B158","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1038\/s41598-021-83974-8","article-title":"Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men","volume":"11","author":"van den Hoek","year":"2021","journal-title":"Sci. Rep."},{"key":"2022092308210108600_B159","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care."},{"key":"2022092308210108600_B160","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"2022092308210108600_B161","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol. Commun."},{"key":"2022092308210108600_B162","doi-asserted-by":"publisher","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","article-title":"Metabolic liver disease in diabetes - From mechanisms to clinical trials","volume":"111S","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"2022092308210108600_B163","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2022092308210108600_B164","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejphar.2012.04.028","article-title":"Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes","volume":"685","author":"Qiang","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"2022092308210108600_B165","article-title":"Losartan Prevents Hepatic Steatosis and Macrophage Polarization by Inhibiting HIF-1alpha in a Murine Model of NAFLD","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2022092308210108600_B166","doi-asserted-by":"publisher","first-page":"100412","DOI":"10.1016\/j.jhepr.2021.100412","article-title":"Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD","volume":"4","author":"van der Graaff","year":"2022","journal-title":"JHEP Rep."},{"key":"2022092308210108600_B167","doi-asserted-by":"publisher","first-page":"25776","DOI":"10.1074\/jbc.M116.752311","article-title":"Glucocorticoid Receptor beta Induces Hepatic Steatosis by Augmenting Inflammation and Inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) alpha","volume":"291","author":"Marino","year":"2016","journal-title":"J. Biol. Chem."},{"key":"2022092308210108600_B168","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12944-017-0432-7","article-title":"Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice","volume":"16","author":"Verbeek","year":"2017","journal-title":"Lipids in Health Dis."},{"key":"2022092308210108600_B169","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/147323000603400309","article-title":"Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes","volume":"34","author":"Yu","year":"2006","journal-title":"J. Int. Med. Res."},{"key":"2022092308210108600_B170","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1478-3231.2012.02774.x","article-title":"Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"key":"2022092308210108600_B171","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40814-018-0306-4","article-title":"A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease","volume":"4","author":"Vos","year":"2018","journal-title":"Pilot Feasibility Stud."},{"key":"2022092308210108600_B172","doi-asserted-by":"publisher","first-page":"587140","DOI":"10.1155\/2013\/587140","article-title":"Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)","volume":"2013","author":"Hirata","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"2022092308210108600_B173","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"2022092308210108600_B174","doi-asserted-by":"publisher","first-page":"e0240338","DOI":"10.1371\/journal.pone.0240338","article-title":"Regulation of gene transcription by thyroid hormone receptor beta agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"15","author":"Luong","year":"2020","journal-title":"PloS ONE"},{"key":"2022092308210108600_B175","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"2022092308210108600_B176","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-beta improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"2022092308210108600_B177","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13578-016-0113-7","article-title":"Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD","volume":"6","author":"Sinha","year":"2016","journal-title":"Cell Biosci."},{"key":"2022092308210108600_B178","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"2022092308210108600_B179","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/MCO.0b013e328357f747","article-title":"Vitamin E and nonalcoholic fatty liver disease","volume":"15","author":"Pacana","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"2022092308210108600_B180","doi-asserted-by":"publisher","first-page":"1756284820974917","DOI":"10.1177\/1756284820974917","article-title":"The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"13","author":"Abdel-Maboud","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"key":"2022092308210108600_B181","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020179","article-title":"Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin","volume":"11","author":"Thomas","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"2022092308210108600_B182","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102975","article-title":"Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)","volume":"26","author":"Gordon","year":"2021","journal-title":"Molecules"},{"key":"2022092308210108600_B183","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1152\/physiolgenomics.00028.2019","article-title":"RNA sequencing in human HepG2 hepatocytes reveals PPAR-alpha mediates transcriptome responsiveness of bilirubin","volume":"51","author":"Gordon","year":"2019","journal-title":"Physiol. Genomics"},{"key":"2022092308210108600_B184","doi-asserted-by":"publisher","first-page":"108072","DOI":"10.1016\/j.abb.2019.108072","article-title":"CRISPR Cas9-mediated deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation","volume":"672","author":"Gordon","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"2022092308210108600_B185","doi-asserted-by":"publisher","first-page":"35","DOI":"10.20455\/ros.2018.809","article-title":"A Novel Fluorescence-Based Assay for the Measurement of Biliverdin Reductase Activity","volume":"5","author":"Adeosun","year":"2018","journal-title":"React. Oxyg. Species (Apex)"},{"key":"2022092308210108600_B186","doi-asserted-by":"publisher","first-page":"F323","DOI":"10.1152\/ajprenal.00495.2017","article-title":"Loss of biliverdin reductase-A promotes lipid accumulation and lipotoxicity in mouse proximal tubule cells","volume":"315","author":"Adeosun","year":"2018","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"2022092308210108600_B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2018.06.003","article-title":"Bilirubin, a new therapeutic for kidney transplant?","author":"Sundararaghavan","year":"2018","journal-title":"Transplant. Rev. (Orlando)"},{"key":"2022092308210108600_B188","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/MPG.0b013e318291fefe","article-title":"Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children","volume":"57","author":"Puri","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"2022092308210108600_B189","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/jgh.12155","article-title":"Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis","volume":"28","author":"Salomone","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2022092308210108600_B190","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1365-2036.2012.05114.x","article-title":"Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH)","volume":"35","author":"Hjelkrem","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2022092308210108600_B191","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10654-019-00589-0","article-title":"Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study","volume":"35","author":"Kunutsor","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"2022092308210108600_B192","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3350\/cmh.2012.18.4.357","article-title":"Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease","volume":"18","author":"Jang","year":"2012","journal-title":"Clin. Mol. Hepatol."},{"key":"2022092308210108600_B193","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3350\/cmh.2012.18.4.383","article-title":"Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease","volume":"18","author":"Kwak","year":"2012","journal-title":"Clin. Mol. Hepatol."},{"key":"2022092308210108600_B194","article-title":"Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults","author":"Choi","year":"2011","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"2022092308210108600_B195","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1753-0407.2011.00138.x","article-title":"Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese","volume":"3","author":"Wu","year":"2011","journal-title":"J. Diab."},{"key":"2022092308210108600_B196","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4021\/jocmr425w","article-title":"High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999 - 2006","volume":"2","author":"Cheriyath","year":"2010","journal-title":"J. Clin. Med. Res."},{"key":"2022092308210108600_B197","first-page":"495","article-title":"Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population","volume":"66","author":"Guzek","year":"2012","journal-title":"Przegl. Epidemiol."},{"key":"2022092308210108600_B198","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1089\/jwh.2010.2453","article-title":"Inverse association between total bilirubin and metabolic syndrome in rural korean women","volume":"20","author":"Kwon","year":"2011","journal-title":"J. Womens Health"},{"key":"2022092308210108600_B199","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12020-010-9417-2","article-title":"Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population","volume":"39","author":"Jo","year":"2011","journal-title":"Endocrine"},{"key":"2022092308210108600_B200","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1620\/tjem.221.133","article-title":"High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy","volume":"221","author":"Han","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"key":"2022092308210108600_B201","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1542\/peds.2008-3087","article-title":"Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease","volume":"124","author":"Lin","year":"2009","journal-title":"Pediatrics"},{"key":"2022092308210108600_B202","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9090889","article-title":"Rats Genetically Selected for High Aerobic Exercise Capacity Have Elevated Plasma Bilirubin by Upregulation of Hepatic Biliverdin Reductase-A (BVRA) and Suppression of UGT1A1","volume":"9","author":"Hinds","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"2022092308210108600_B203","doi-asserted-by":"publisher","first-page":"30051","DOI":"10.1038\/srep30051","article-title":"Features of an altered AMPK metabolic pathway in Gilbert's Syndrome, and its role in metabolic health","volume":"6","author":"Molzer","year":"2016","journal-title":"Sci. Rep."},{"key":"2022092308210108600_B204","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.18632\/oncotarget.12277","article-title":"Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?","volume":"8","author":"Sundararaghavan","year":"2017","journal-title":"Oncotarget"},{"key":"2022092308210108600_B205","doi-asserted-by":"publisher","first-page":"154925","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/136\/18\/1347\/937460\/cs-2022-0572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/136\/18\/1347\/937460\/cs-2022-0572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:22:00Z","timestamp":1663921320000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/136\/18\/1347\/231842\/Molecular-mechanisms-of-metabolic-associated-fatty"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":205,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9,30]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20220572","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9]]},"published":{"date-parts":[[2022,9]]}}}